trending Market Intelligence /marketintelligence/en/news-insights/trending/TnexGKOA1-xjhGawWyuDVg2 content esgSubNav
In This List

GSK's 2-drug HIV regimen effective as every-other-month jab in study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GSK's 2-drug HIV regimen effective as every-other-month jab in study

ViiV Healthcare Ltd.'s two-drug regimen for HIV was effective as an injection administered every two months, a late-stage study showed.

The phase 3 trial, dubbed Atlas-2M, evaluated the antiviral activity and safety of its medicine cabotegravir combined with Johnson & Johnson's Edurant, or rilpivirine, when injected every two months in adults with HIV-1 infection whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine.

In previous late-stage studies, the company injected the two-drug therapy once every month.

U.K.-based Viiv Healthcare plans to present detailed results of the study at an upcoming scientific meeting.With Atlas-2M's positive results, HIV patients could maintain viral suppression with just a total of six treatments each year instead of taking daily oral treatments, Viiv Healthcare noted.

The two-drug treatment regimen is currently under review by regulatory authorities in the U.S., EU and Canada. The company's application is under priority review by the U.S. Food and Drug Administration and a decision is expected to be available Dec. 29.

ViiV Healthcare is a global specialist HIV company majority-owned by GlaxoSmithKline PLC. Pfizer Inc. and Japan's Shionogi & Co. Ltd. are also shareholders in the company.